Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

Song, In‐Uk; Heldmann, F.; Rudwaleit, Martín; Haibel, Hildrun; Weiß, Anja; Braun, J.; Sieper, Joachim

doi:10.1136/ard.2010.145946

Cited by 157 publications

(89 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Song and colleagues studied the efficacy of ABA in 30 patients with AS (15 TNF-α-inhibitor-naive patients and 15 nonresponders to TNF-α inhibitors) and demonstrated that ASAS-40 was reached by 13% of the TNF-α-inhibitor-naive patients and by none of the nonresponders to TNF-α inhibitors [Song et al 2011]. More recently, Lekpa and colleagues showed the lack of efficacy of ABA in axial SpA [Lekpa et al 2012a].…”

Section: Biological Therapiesmentioning

confidence: 99%

“…According to the recommendations of the Assessment of Spondyloarthritis International Society (ASAS) and the European League Against Rheumatism (EULAR), the first-line therapy of SpA is represented by nonsteroidal anti-inflammatory drugs (NSAIDs) and nonpharmacological treatment [Wendling et al 2014;Braun et al 2011]. NSAID therapy effectively controls joint symptoms and signs of axial involvement [Escalas et al 2010;Benhamou et al 2010], giving no significant effects on laboratory markers of inflammation [Escalas et al 2010]; moreover, some studies suggest NSAIDs have beneficial effect on axial structural damage [Wendling, 2013].…”

Section: From Nonsteroidal Anti-inflammatory Drugs To Traditional Dismentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Caso

Costa

Puente

et al. 2015

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients' quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.

show abstract

Section: Biological Therapiesmentioning

confidence: 99%

Section: From Nonsteroidal Anti-inflammatory Drugs To Traditional Dismentioning

confidence: 99%

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Caso

Costa

Puente

et al. 2015

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…45 No evidence currently supports efficacy of other biologics in AS. An open-label study of abatacept did not show evidence of major response, 46 and rituximab was ineffective in patients who had failed to respond to TNF inhibitors, but clinically significant responses were seen in TNF inhibitor-naïve patients. 47 DMARDs and NSAIDs have been implicated in liver damage.…”

Section: New Biologicsmentioning

confidence: 99%

Drug therapy of inflammatory arthritis

Gullick

Scott

2012

Clinical Medicine

View full text Add to dashboard Cite

-Inflammatory arthritis involves a diverse range of conditions in which an uncontrolled immune response occurs. A number of advances in assessment, diagnosis and treatment have been made in recent years. Drug therapies used in inflammatory arthritis aim to reduce symptoms and suppress inflammation, joint damage and disability. In rheumatoid arthritis (RA), immunosuppression is used in almost all patients, with an emphasis on early aggressive treatment to achieve clinical remission. This approach is less successful in spondylarthropathies, for which non-steroidal anti-inflammatory drugs remain first-line therapy. The use of biologic therapies has increased dramatically across a range of indications and has resulted in improved outcomes for patients. These agents are associated with an increased risk of infection, particularly tuberculosis in patients receiving tumour necrosis factor inhibitors. Alternative biologics have entered clinical practice for RA in recent years, and clinical trials using these agents, as well as novel non-biologic therapies, are in progress for RA and other conditions.

show abstract

“…One of the newer TNF-blocking agents, certolizumab pegol, has not been studied in patients with SpA. Other biological agents, such as interleukin-1 receptor antagonist (anakinra), rituximab, tocilizumab and abatacept, have only been studied in small groups of patients with SpA and did not show much efficacy [Tan et al 2004;Haibel et al 2005;Song et al 2010Song et al , 2011aLekpa et al 2012].…”

Section: General Treatment Of Spondyloarthritismentioning

confidence: 99%

Management and evaluation of extra-articular manifestations in spondyloarthritis

Horst‐Bruinsma

Nurmohamed

2012

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Spondyloarthritis (SpA) is a chronic inflammatory disease with either predominantly axial symptoms of the spine and sacroiliac joints (axial SpA, including ankylosing spondylitis) or predominantly arthritis (peripheral SpA). Next to these spinal and articular symptoms, many patients with SpA also have extra-articular manifestations (EAMs). EAMs associated with SpA include anterior uveitis (25-30%), psoriasis (10-25%) or inflammatory bowel disease (IBD) (5-10%) and cardiovascular manifestations. Peripheral arthritis occurs in approximately 30% of patients, especially in large joints, and shows an asymmetrical, oligoarticular pattern. Other common joint complaints are due to enthesitis, which manifest as extra-articular bony tenderness in areas such as the Achilles tendon. Acute anterior uveitis presents with acute pain, loss of vision and redness in one eye that usually subsides spontaneously after several weeks. Rapid treatment by an ophthalmologist is required to prevent synechiae formation which could ultimately result in glaucoma and blindness. Although less common, organ involvement in SpA can also be located in the heart, lungs or kidneys. The risk of cardiovascular events is increased in SpA. Cardiac manifestations can involve the aortic valve (1-10%) or the atrioventricular node and the risk of atherosclerotic events is increased in this group. Treatment of SpA includes physical exercise and nonsteroidal anti-inflammatory drugs (NSAIDs), and in case of peripheral arthritis, sulphasalazine can be added. When there is insufficient response to NSAIDs, tumor necrosis factor blockers, especially infliximab, etanercept, adalimumab and golimumab, are very effective in treating axial manifestations, arthritis, enthesitis and psoriasis. Anterior uveitis in SpA can be treated adequately by the ophthalmologist and in the case of refractory uveitis, treatment with adalimumab and infliximab seems to be more effective compared with etanercept. When IBD occurs with SpA, the use of NSAIDs should be minimized, except for celecoxib, and infliximab or adalimumab are preferred to etanercept. The incidence of atherosclerotic events or SpA-specific cardiac manifestations may be decreased by cardiovascular risk management or effective antirheumatic treatment. Overall it is important to realize that extra-articular manifestations frequently occur in patients with SpA and should be taken into account in the choice of treatment.

show abstract

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

Abstract: In this pilot open-label AS study a major response was not observed.

Cited by 157 publications

References 18 publications

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Drug therapy of inflammatory arthritis

Management and evaluation of extra-articular manifestations in spondyloarthritis

Contact Info

Product

Resources

About